

NIFTY KEY LEVELS

Support 1 : 10750 Support 2 : 10700 Resistance1: 10950 Resistance2: 11000

Events Today

Dividend

PTC, RAJESHEXPO, RAMCOCEM, SIEMENS, SONATSOFTW, SREINFRA, SUNDRMFAST, TATASTEEL, VOLTAS, WELCORP, ADANIGREEN, ALLCARGO, REGENCY, AHLWEST, SUPERSHAKT, SURYAAMBA, SHIVTEX, JCHAC, NCC, BNKCAP, SAYAJIIND, RAJPALAYAM, INDUSINDBK, GAIL, ABMKNO, SHIVAMILLS, MOTHERSUMI, BASML, OIL, MAGNAELQ, VARROC, GRASIM, NICCOPAR, GRANULES, TRIDENT, GODREJCP, STERTOOLS, CASTROLIND, MAGNAELQ.

Ex-Date: 08.08.2019

Results

ABBOTINDIA, ADANIENT, ADANITRANS,
ADVENZYMES, COFFEEDAY, CUB, EMAMILTD,
ENDURANCE, ENGINERSIN, GESHIP, GNFC,
GODREJPROP, GPPL, GREAVESCOT,
HEXAWARE, ICIL, INFIBEAM, JSLHISAR,
MAXINDIA, MGL, NBCC, NBVENTURES,
PAGEIND, RADICO, RCF, TATACHEM, TEXRAIL,
THERMAX, UCOBANK, ULTRACEMCO,
AKSHOPTFBR, AKZOINDIA, APARINDS, ARIES,
AVADHSUGAR, CAPACITE, CAREERP,
CLNINDIA, DAAWAT, DREDGECORP,
DYNAMATECH, FAIRCHEM, GANGESSEC,
GOKULAGRO, HCG, HIRECT,

Bonus

RITES 1:4

Ex-Date: 08.08.2019

Please refer to page pg 9 for Bulk deals, Dividends, Bonus, Spilts, Buyback.



Yesterday, Nifty opened positive at 10958.10 and made a high of 10975.65. From there it moved towards the low of 10835.90 and closed negative at 10855.50. On sectoral front only IT , PHARMA and MEDIA traded positive, whereas rest of the indices closed with negative bias. India VIX closed positive by 4.73% at 16.88

Fresh sell-off was witnessed in Nifty yesterday and it validates our view that the index has not yet completed its bottom out process. Immediate crucial support of Nifty is at 10800 and a closing below this level is likely to take the index further lower to 10600 in the near future. In short term (10500-10600) zone would act as strong support areas of Nifty. So we should initiate fresh long position either in 10500-10600 zone or only above 200 DMA (currently is at 11160).

Indian Market						
Index (Prev. Close)	Value	% Change				
SENSEX	36,690.50	-0.77%				
NIFTY	10,855.50	-0.85%				
BANK NIFTY	27,702.05	-1.14%				
Global	Market					
Index (Prev. Close)	Value	% Change				
DOW	26,007.07	-0.09%				
NASDAQ	7,862.83	0.38%				
CAC	5,266.51	0.61%				
DAX	11,650.15	0.71%				
FTSE	7,198.70	0.38%				
EW ALL SHARE	17,792.60	0.56%				
Morning Asian Market (8	:30 am)					
SGX NIFTY	10,858.50	-0.06%				
NIKKIE	20,571.50	0.27%				
HANG SENG	26,072.00	0.29%				
Commodi	ty Market					
Commodity(Prev. Close)	Value	% Change				
GOLD	38,218.00	1.92%				
SILVER	43,779.00	3.04%				
CRUDEOIL	57.72	2.65%				
NATURALGAS	149.00	-1.39%				
Currenc	y Market					
Currency (Prev. Close)	Value	% Change				
RS./DOLLAR	70.88	0.09%				
RS./EURO	79.32	-0.03%				
RS./POUND	86.00	-0.20%				

Bond Yield					
Bond yield (Prev. Close)	V	'alue	% Change		
G-sec 10YR : IND		6.37	0.49%		

% Change in 1 day

Institutional Turnover						
FII						
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)			
07-Aug-19	5240	5624	(384)			
Aug-19	25083	33536	(8453)			
2019	805360	774696	31599			
	DI	I .				
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)			
07-Aug-19	3991	3459	532			
Aug-19	24661	16595	8066			
2019	545975	525125	20851			

Quote of the Day: "Risk comes from not knowing what you are doing."



GSKCONS NEUTRAL 08-Aug-19

GSKCONS has reported numbers better than our expectation, sales grew by 8% YoY to Rs 1194 cr(vs expec. Rs 1219 cr) while posted strong PAT growth 24% YoY to Rs 248 cr(vs expec. Rs 220 cr). The company's pricing action with forward cover on key inputs helped in gross margin expansion by 38 bps while cost efficiency measures and better allocation has helped in EBITDA margin expansion by 268 bps. Going forward, better traction from new launched products, distribution expansion and lower unit products to drive sales growth. While pricing action taken by the company and cost efficiency measure will help in maintenance of margin. We continue to value the company at 33xof FY20e eps and maintain our previous target price of Rs 7976. As there is very limited upside from here for the company we maintain Neutral rating on it.

KEC BUY 08-Aug-19

Strong uptick in execution of Power T&D projects both in Domestic and International market will further enhance the outlook. While, growth trajectory of the Non T&D business will continue to lead by the Railway business. The execution and order book of the civil business is subdued and will be key thing to look out, though the segment contribution is quite small. The overall order inflow is likely to pick up from H2FY20. We largely maintain our estimates for the FY20/21. We continue to value the stock at 15x FY21E EPS and arrived at target price of Rs 418 per share. We maintain our BUY rating on the stock.

RBI - Monetary Policy MACRO 08-Aug-19

Monetary Policy Committee in its 3rd bi-monthly policy decided to reduce the repo rate by 35 basis points to 5.40% from 5.75%. As a result of which the reverse repo rate now stands adjusted at 5.15% and Marginal Standing Facility at 5.65% while keeping the stance unchanged at accommodative. The longer term growth projections have been marginally revised downwards for a fourth term in a row. whereas the inflation projection has marginally creeped up. A higher than consensus rate cut is a welcome move from the RBI which will help in repairing the credit cycle which is in trouble right now. Acceptance by the RBI of a cooling GDP growth estimates is a sign that the government should look for some fiscal measures along with the monetary measures by the RBI to reinvigorate growth in India.

IRB NEUTRAL 07-Aug-19

The deal with the GIC, Singapore comes at very important juncture. The deal will help IRB to deleverage its balance sheet which will result into interest cost saving of Rs 300-350 Cr annually and will have investor for the future projects as well. But the appointment date on the 2 HAM projects are delaying quarter after quarter and will remain overhang on the future revenue performance. Considering the delay in appointment date we have reduce our estimated revenue for FY20/21 by 13/8%. We maintain our target price of Rs 110 (7.5x FY21E EV/EBITDA) and NEUTRAL stance on the stock.

MINDTREE UNDER REVIEW 07-Aug-19

Mind tree has always been the one of top contender in mid cap space when it comes to digital business (49.5% of overall revenue). However with recent turmoil in the top management, 1QFY20 resulted in weakest quarter for the company in recent times. Revenue remained muted (growth of 0.8%QoQ) While margin declined by 390bps sharply. Going forwards, Despite healthy deal wins during the quarter , significant attrition at the Top leadership level (three founders and few other KMPs have resigned in last one month) and deteriorating financial performance have raised a concern for sustainable revenue growth for FY20.Although the company has on boarded the new CEO however one has to wait for the strategic roadmap that the new management takes up to improve Mind tree's performance in the coming quarters. Until we see further clarity on these developments, and stability in terms of personnel and attrition, we keep our rating Under Review



METROPOLIS 1QFY20 Concall Highlights:

Industry Outlook:
☐ The diagnostic industry is expected to grow to USD 12 billion in FY20 from USD 9 billion in FY18.It is one of the better
growing segment in healthcare industry.
Organised player's have less than 15-20% market share leading ample room for growth. The company is confident of
growing above the industry growth rate.
☐ The growth opportunities lie in scientific up selling, Preventive and wellness services for the company.
Other Highlights:
☐ The EBITDA margins would have been higher by 0.9% if exclude lab on lease. The lab on lease contract existed in 1QFY19
which were 11 in numbers moved EBITDA from 6.5% to 14.5% in 1QFY20.It may be at 20-22% in the next year. The new
lab on lease contract started post 1QFY19 which are 12 in number diluted the total lab on lease EBITDA to 8.8%.
☐ CAPEX of Rs 20 Cr expected for FY20, half towards medical equipment, half towards IT spends.
☐ B2C share in revenue mix stood at 45% in 1QFY20 as against 43% in 1QFY19.BAC share in focused cities stood at 56% in
1QFY20 as against 51% YoY. Domestic revenue contribution stood at 95%.
☐ GRL contribution stands at 50% to total revenue.
☐ The company has not taken any major price hikes since last three years and are expecting to do later in the end of
FY20.Realisation is more or less expected to be same for the full year FY20.
☐ Semi specialised tests segment faces more competition than regular or specialised one.
☐ Going ahead the company does not want to add more labs, the focus remains on expanding through the route of third
party collection centres.
\Box In wellness segment the prices of the companies are higher as against the competitor, the reason being focus on the
quality of the products provided.
☐ 71% of the network of the company is young and major retail growth came from this young network only. Maturity of
this young network will allow the company to increase their revenue.
☐ The wellness segment grew by 40% YoY in 1QFY20 and contribution to revenue stood at 6.5%.
☐ For the company, Q1 is the leanest quarter and Q2, Q4 best and Q3 being subdued due to the festivals.
☐ Five new labs (Green field and Lab on Lease) are operational in Q1FY20.
□ NACO continues to be smaller percentage of the revenue of the company. It broke even last year and is expected to be profitable this year.
☐ 1-2 cities each expected to be added in focused cities and seeding cities as a part of expansion strategy by the end of

FY20.



MINDAIND 1QFY20 Concall Highlights:

☐ The industry growth volumes in 2W, 3W, 4W and off loaders declined by 10%, 9%, 12% and 22% respectively during 1QFY20.
☐ The company will continue to outperform the industry growth in FY20.
☐ The management expects pre-buy and good festive season in 2HFY20 may improve some demand.
Over short and medium term, the management expects 6-8% growth in the auto sector.
Business Division:-
a) Switches – contributes 37% to the total revenue
- Revenue – Rs. 532 crs in 1QFY20.
- In 4W business, the company has secured new orders for newly launched models from new customers and also from Hyunda
and further, this momentum from Hyundai is expected to continue.
b) Lightings – Contributes 24% to the total revenue
- Revenue – Rs. 339 crs in 1QFY20
- There were better volumes in some of new launches. Lamps were mainly used in newly launched models by the OEMs which
were supported by higher LED content.
c) Acoustics – contributes 12% to the total revenue
- Revenue – Rs. 178 cr in 1QFY20
- The domestic business upbeat despite volume cuts and Clarton Horn (Mexico) is under stabilization
d) Light metal technology – Contributes 14% to the total revnue
- Revenue – RS. 200 crs in 1QFY20
- Better operational efficiency, favorable movement of commodity price along with Improved customer mix aided growth
e) Others – Contributes 14% to the total revenue
- Revenue – Rs. 190 crs in 1QFY20
- iSYS and Katolec have contributed to top line growth
- RPAS and front air bags mandatory in 4W (PV) segment with effect from July 19
Update on "Scheme of Arrangement"
- HSSL Merger: SEBI has approved the scheme and the company expects to file the scheme with NCLT within this month.
- Merger of 4 WOS: Secured Creditors consents are being obtained and the company expects to file the scheme with NCL
within this month and merger to be consummated by Q4FY20.
☐ Sensor business has received new orders from Kawasaki and PSA for engine speed and oil temperature sensors.
☐ Minda Kosei Aluminum Wheels Pvt. Ltd. has received orders of Rs. 87 Cr. per annum from OEMs: Rs. 54 Cr. from M&M and
Rs. 33 Cr. from MSIL
BS-VI expected implementation by 2020 will benefit the company with strong demands for Sensors (BS VI) and Engine
related Sensors in association with Sensata, US and Advance Filtration and Canisters.
☐ Capacity Utilization from new facilities Minda Rika, Minda Kosei and Minda Koraku is at 50%.
Existing business capacity utilization - Lighting business – 80-85% both for 2W and 4W. In 4W, the company has got new orders from new business in models like
Mahindra XUV 300 and Tata Harrier.
- Alloy Wheel business – At Bawal plant – 75% and at Gujurat plant – 50%.
 - Ascoutics – 90% capacity utilization. - Switches – At Manesar plant – 75% and Gujarat 50% for 4W. For 2W it is at 80%.
The sensor and controllers business are expected to do well going forward. The annual revenue expected to be generated
from this segment is Rs. 130 crs.
☐ The sensors business is expected to contribute Rs. 120-130 crs to the revenue in FY20.
☐ The new plant Sensata in US for sensors is expected to open in 2HFY20.
— The new plant sensulu in as for sensors is expected to open in 2111 120.

☐ Capex – Total of Rs. 475 crs in which Rs. 350 crs will be for Greenfield expansion project and Rs. 125-150 crs from brownfield

☐ The revenue from telematics is expected to be Rs. 50 crs for FY20 and Rs. 80-90 crs for FY21.

☐ The Isys acquisition has added Rs. 11-14 crs to the revenue this quarter.

☐ Roki Minda revenue for the quarter was Rs. 100 crs.

expansion.



KEC Q1FY20 Concall highlights

SAE 1QFY20 revenue includes execution of 1 EPC project. Execution of other 2 EPC projects in Brazil has also commenced.
Currently negotiating with the private developer and orders from Brazil are expected to come in from 3Q and 4Q FY20.
AE margin is in line with the expectation but it is lower than earlier estimates due to increase in transportation cost and
higher steel price. Currently margin in the range of 8.5% -9% and it will touch double digit by the year end as the EPC
projects started contribution in revenue.
Maintain Revenue guidance at 15-20% with EBITDA margin being 10-10.5%.
Revenue growth in international market is expected to continue in FY20.
Company is in L1 of Rs 3500 Cr majorly in T&D, Railways and Civil.
H2FY20 is expected robust in terms of Domestic Inflows.
Bangladesh, Nepal, Afghanistan and Far East will continue to see orders intake in T&D.
Order inflows are expected to grow by 15-20%.
Railway business is focusing on RRTS, ROB in addition to conventional railways.
Railways orders are expected to flow from Q3FY20. L1 of Rs 1000 Cr in Railways is expected to be awarded in Q3FY20.
Execution of 150MW solar project in India is on track. Indian market will stay muted in solar business.
L1 in medium size multilateral funded solar EPC project in International market.
In Civil project, company has started focusing on Government projects including commercial buildings, Metro elevated
corridors, Airport extension etc.
Capex of Rs 150-170 Cr is expected in FY20 of which Rs 40 Cr will be for Railways and Rs 30-40 Cr for factory.
Forex loss of Rs 4 Cr in 1QFY20 as against Forex profit of Rs 20 Cr.
Rs 5 Cr has been naid towards prenayments



ZENSARTECH 1QFY20 concall highlights:

Core business: The company had solid growth in core business of 3.9%QoQ and 19.9%YoY in cc terms respectively during the quarter .The core business now contributes 96.1% of the overall revenue.
Margin: Excluding the INDAS impact which positively impacted 1.4% to margin, the company saw margian remained flat owing to adverse impact of 30bps from exchange rate realization and 100bps due to reduction in utilization .Also investment
in Fresher headcount also impacted the margins .2QFY20 will see wage revision however with the levers like automation and more CIS business comes in, the management believes it has levers to offset the wage impact during the course of the year. Management continues to target to hit the level of 15% of EBITDA margin.
Accounting standard change: Due to change in INDAS 116, The Company saw interest cost of 600k increase and depreciation increase is roughly around 1.8million dollars
PAT de-grew by 8.3%QoQ(absolute term USD1million)was due to reduced other income that came in last quarter on account of sale of Row business and also marginal INDAS116 impact which was partially offset by increase in exchange gain.
Digital business: In 1QFY20 company digital revenue accounted for 48.5% of the overall business, a growth of 6.7% sequentially and 28.3%YoY in dollar terms. Zensar rod next and solutions continue to be integral part of all the large deal wins so far.
Deal wins: the company remains optimistic with large deal momentum in FY20 by winning key deals across region from existing and new client .This Quarter Company booked deal worth of USD160mn (60% is net new TCV)majorly coming from key renewals.TTM total booking was at USD700+ million. Overall pipeline continues to remain solid and is above
USD1.1billion as of date. The split between application business and cloud Infrastructure business is roughly about 60%/40% of the wins.
Segment wise: In IMS, The Company is seeing strong traction in CIS next gen services. On application side as called out in previous quarter, mostly the company focus has been towards digital enterprise that is where the company is seeing traction in financial services and technology verticals. Retail has been soft sector (legacy application business) for the company, the management still thinks there will some headwinds left and more work has to be done. Thus expect pain to continue for few quarters.
Non core business: The company is focusing on uplifting both the revenue and margin So as it improves, the company will relook for exit process.
Patents: The company sustains focus has helped to double the tag of patents granted from the last quarter. While the company continues to file more patents particularly in the areas like AI and automation .Total patent filing now stands at 91 out of which 10 has been granted.
Headcount: 1QFY20 saw the company adding more associates .At the end of 1QFY20, the global headcount stood at 10166, a net addition of 418 and 1336associates on sequential and YoY basis respectively. Attrition in 1QFY20 was at 16.7%.
Demand environment: Management sees demand environment healthy however there is noticeable trend of reducing deal sizes tenures which company believe will better for the company. The company will continue to remain invested to continue the growth. Trade war if happens possibility will impact tech investment however does not see any impact as of now.



M&M 1QFY20 Concall Highlights:-

	The domestic tractor industry is expected to grow by 6-8% in remaining 8 months from September 2019 to April 2020 led by normal
	monsoons, higher Rabi sowing, base effect, pre-buy and upcoming festive season.
	PV demand continues to be impacted by the slowing down of the overall economy along with tight credit conditions and delayed
	monsoon which has impacted consumer sentiment in both urban and rural India.
	Increasing road tax and higher registration rates may further impact the demand going forward.
	The stress in the agri sector and finance availability has impacted the demand for LCV 2-3.5T and HCV segment.
	The slowing down of economic activity coupled with the increase in freight capacity of existing fleet due to implementation of new
	axle loading norms has resulted in many transporters either reducing or temporarily suspending their fleet purchase plans for CVs.
	Tractor demand in Q1FY20 remained sluggish and was adversely impacted due to a weak sentiment in the agri economy resulting
	from the delay in SW monsoon, poor spatial distribution in June and weak agricultural incomes impacted by poor price realization.
	The company is focusing on the exports market going ahead.
	Ssangyong business – This business has been impacted due to slowdown in Korea as well as other international markets.
	The loss from Mahindra USA business which is for tractors is expected to reduce by 50% in FY20.
	The company has taken price increase both in tractor and auto segment.
	he petrol:diesel mix is expected to be 50:50 after BS-VI implementation.
	Dealer inventory level is 2000-3000 tractors which is approximately 3 weeks.
	The company is not facing any dealer financing issues.
	Debt equity ratio continues to be at 0.1.
	On the electric vehicle side, the management expects the demand in 4 wheelers to improve with latest GST rate cuts, and affordable
	shared mobility services. The company has also made investments in electric 2-wheeler.
	Exceptional items of Rs. 1367.05 crores during 1QFY20 mainly represents: (a) gain on sale of shares by M&M benefit trust; and (b)
_	gain on buy back by an associate / transfer of certain long term investments.
	Other income of Rs. 150.39 includes dividend received from Subsidiaries, Associates and Joint ventures during the quarter.
CII	PLA 10FY20 concell highlights:
<u>CII</u>	PLA 1QFY20 concall highlights:
	PLA 1QFY20 concall highlights: India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business.
<u> </u>	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential
_ _	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa-Tender business to rebase in-line with new tender supplies in Q2FY20.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China. On the specialty segment- The Company expects to launch Tramadol along with Zemdri by the end of the next year, and would
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China. On the specialty segment- The Company expects to launch Tramadol along with Zemdri by the end of the next year, and would require building the filed force for the same.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China. On the specialty segment- The Company expects to launch Tramadol along with Zemdri by the end of the next year, and would require building the filed force for the same. Cipla Ltd and Eight Roads have signed a definitive agreement for Cipla Ltd to acquire the minority stake of Eight Roads in CHL, thereby
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China. On the specialty segment- The Company expects to launch Tramadol along with Zemdri by the end of the next year, and would require building the filed force for the same. Cipla Ltd and Eight Roads have signed a definitive agreement for Cipla Ltd to acquire the minority stake of Eight Roads in CHL, thereby giving Cipla Ltd 100% ownership interest of CHL. R&D expenditure for the quarter were Rs. 261 crs (6.5% of sales), for the full year R&D spend is expected to be 7-8% of sales as respiratory trials for generic Advair is on track.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China. On the specialty segment- The Company expects to launch Tramadol along with Zemdri by the end of the next year, and would require building the filed force for the same. Cipla Ltd and Eight Roads have signed a definitive agreement for Cipla Ltd to acquire the minority stake of Eight Roads in CHL, thereby giving Cipla Ltd 100% ownership interest of CHL. R&D expenditure for the quarter were Rs. 261 crs (6.5% of sales), for the full year R&D spend is expected to be 7-8% of sales as respiratory trials for generic Advair is on track. For the India sales, the business is expected to be back on track by Q2FY20 as the new distributors will take time to ramp up.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China. On the specialty segment- The Company expects to launch Tramadol along with Zemdri by the end of the next year, and would require building the filed force for the same. Cipla Ltd and Eight Roads have signed a definitive agreement for Cipla Ltd to acquire the minority stake of Eight Roads in CHL, thereby giving Cipla Ltd 100% ownership interest of CHL. R&D expenditure for the quarter were Rs. 261 crs (6.5% of sales), for the full year R&D spend is expected to be 7-8% of sales as respiratory trials for generic Advair is on track.
	India sales declined by 12% YoY to 1355 crs this quarter. 170-200 crs sales impact was on account of realignment of distributors in the trade generics, another 60 crs impact was due to dispatch deferrals to the month of July in Prescription business. US sales Improved 61% YoY to US\$ 161 mn on account of Cinacalcet contribution and growth in the base business. On a sequential basis, sales are almost flat due to lack of any meaningful products. Emerging market sales declined by 43% to US\$ 40 mn, impacted by dispatch deferrals to July by US\$14.5mn. As per IQVIA (IMS) MAT Jun'19, South Africa business grew at more than two times the market at 7.3% in the private market. South Africa- Tender business to rebase in-line with new tender supplies in Q2FY20. South Africa- Acquired portfolio of Mirren in the OTC space delivered over 10% growth. Cipla has acquired worldwide rights of ZEMDRI™ excluding Greater China with its allied assets and limited liabilities from Achaogen Inc. The company sees China to contribute meaningfully in the next 3-5 years; the focus of the company will be to manufacture Respiratory and Oncology products in China. On the specialty segment- The Company expects to launch Tramadol along with Zemdri by the end of the next year, and would require building the filed force for the same. Cipla Ltd and Eight Roads have signed a definitive agreement for Cipla Ltd to acquire the minority stake of Eight Roads in CHL, thereby giving Cipla Ltd 100% ownership interest of CHL. R&D expenditure for the quarter were Rs. 261 crs (6.5% of sales), for the full year R&D spend is expected to be 7-8% of sales as respiratory trials for generic Advair is on track. For the India sales, the business is expected to be back on track by Q2FY20 as the new distributors will take time to ramp up.



Stocks in News:

	Adani Gas (Q1, QoQ) Revenue fell 3.3 percent to Rs 450.6 crore. Net profit rose 4.6 percent to Rs 79.3 crore. Ebitda fel
	3.4 percent to Rs 134.9 crore. Margins stood at 29.9 percent versus 30 percent. Depreciation fell 31 percent to Rs 12.6
	crore versus Rs 18.2 crore.
	Lemon Tree Hotels (Q1, YoY) Revenue rose 11 percent to Rs 140.9 crore. Net loss at Rs 1.7 crore versus Net Profit of Rs
	2.3 crore. Ebitda rose 28.4 percent to Rs 44.7 crore. Margin stood at 31.7 percent versus 27.4 percent. Finance cost rose
	57 percent to Rs 30.9 crore.
	Oracle Financial Software Services (Q1, QoQ) Revenue rose 4.9 percent to Rs 1,275 crore. Net profit rose 15.8 percent to
	Rs 377.4 crore. EBIT rose 16.6 percent to Rs 589.5 crore. Margin at 46.2 percent versus 41.6 percent.
	Adani Power (Q1, YoY) Revenue up 108 percent to Rs 7,805 crore. Net loss of Rs 263 crore vs net loss of Rs 825 crore
	Ebitda up 148 percent to Rs 2,684 crore. Margin at 34.4 percent versus 28.8 percent. Exceptional loss of Rs 1,004 crore in
	June quarter as amount written off on sale of stake in a company.
	Tata Steel (Q1, YoY) Revenue rose 1.3 percent to Rs 35,947.1 crore. Net profit fell 64.3 percent to Rs 693.1 crore. Ebitda
	fell 15.4 percent to Rs 5,376.8 crore. Margin stood at 15 percent versus 17.9 percent.
	HCL Tech (Q1, QoQ) Dollar revenue rose 3.8 percent to \$2,364 million . Revenue rose 2.7 percent to Rs 16,427 crore. Net
	profit fell 12.5 percent to Rs 2,230 crore. EBIT fell 7.8 percent to Rs 2,748 crore. Margin stood at 16.7 percent versus 18.6
	percent. FY20 revenue guidance to grow between 14 percent to 16 percent in constant currency. FY20 EBIT margin
_	guidance between 18.5 percent to 19.5 percent.
Ц	HPCL (Q1, QoQ) Revenue rose 4.5 percent to Rs 70,988.9 crore. Net profit fell 72.7 percent to Rs 811 crore. Ebitda fel
_	68.2 percent to Rs 1643.9 crore Margin stood at 2.3 percent versus 7.6 percent.
Ц	Petronet LNG (Q1, QoQ) Revenue rose 2.7 percent to Rs 86,13.4 crore. Net profit rose 27.3 percent to Rs 560.3 crore.
	Ebitda rose 63.2 percent to Rs 1,023.9 crore. Margin stood at 11.9 percent versus 7.5 percent. Total volumes were 10
	percent up at 225 trillion BTU versus 205 trillion BTU. Higher depreciation and finance cost due to adoption of IND AS 116
_	reduced net profit by Rs 51.6 crore.
Ц	Aurobindo Pharma (Q1, YoY) Revenue rose 28.1 percent to Rs 5,444.6 crore. Net profit rose 39.5 percent to Rs 635.8
_	crore. Ebitda rose 47.1 percent to Rs 1,146.4 crore. Margin stood at 21.1 percent versus 18.3 percent.
	Wipro awarded five-year strategic IT Contract by ADM Aeroports de Montreal.
Ч	Tata Steel executed memorandum of understanding to sell 70 percent of its stake in its Thailand arm to Synergy Metals
	and Mining Fund.
Ч	NBCC has secured total business of Rs 201.77 crore for the months of June and July.

Red: Negative Impact **Green:** Positive Impact **Black**: Neutral.




BULK DEAL						
EXCHANGE	Date	SECURITY NAME	CLIENT NAME	DEAL TYPE	QUANTITY	PRICE
BSE	07-08-19	AKASHDEEP	SECUROCROP SECURITIES INDIA PRIVATE LIMTED	В	161000	34.3
BSE	07-08-19	AKASHDEEP	SANGEETA PAREEKH	S	161000	34.3
BSE	07-08-19	AMFL	MEHTA VIDHI KAMLESH	В	8000	9.69
BSE	07-08-19	AMFL	RIDDHESHKUMAR GIRISHBHAI BHANDARI	В	56000	9.7
BSE	07-08-19	AMFL	BHAVESHKUMAR GIRISHBHAI BHANDARI	В	64000	9.61
BSE	07-08-19	AMFL	MEHTA VIDHI KAMLESH	S	104000	9.62
BSE	07-08-19	JIYAECO	SANTOSH KUMAR AGRAWAL HUF .	В	207839	47.11
BSE	07-08-19	JIYAECO	SANTOSH KUMAR AGRAWAL HUF .	S	207839	47.09
BSE	07-08-19	PUROHITCON	PRANAV MAHENDRA JANI	В	39000	9.26
BSE	07-08-19	PVVINFRA	GKML SOFTWARE TECHNOLOGIES PRIVATE LIMITED	В	45000	22
BSE	07-08-19	PVVINFRA	CTIL MEDIA PRIVATE LIMITED	В	243	23.29
BSE	07-08-19	PVVINFRA	CTIL MEDIA PRIVATE LIMITED	S	44429	22
BSE	07-08-19	SANTOSHIND	IVORY CONSULTANTS PVT LTD	В	44895	287.7
BSE	07-08-19	SANTOSHIND	BINDAL FINVEST PVT LTD	S	24895	287.7
BSE	07-08-19	STL	GOODPOINT COMMODEAL PRIVATE LIMITED	В	20000	144.75
BSE	07-08-19	STL	ARYAMAN BROKING LIMITED	S	20000	144.75
BSE	07-08-19	TISL	B B COMMERCIAL LTD	В	995000	2.57
BSE	07-08-19	TITANSEC	ORATOR MARKETING PRIVATE LIMITED	S	239900	2.76

				Corporate Action	
EXCHANGE	SECURITY CODE	SECURITY NAME	EX- DATE	PURPOSE	RECORD DATE
BSE	504646	BGWTATO	09-08-19	Dividend - Rs 1.0000	-
BSE	509470	BOMOXY-B1	09-08-19	Dividend - Rs 10.0000	-
BSE	532456	COMPUAGE	09-08-19	Final Dividend - Rs 0.4000	-
BSE	542668	EVANS	09-08-19	Final Dividend - Rs 2.2000	-
BSE	509631	HEG	09-08-19	Final Dividend - Rs 50.0000	-
BSE	500210	INGERRAND	09-08-19	Final Dividend - Rs 3.0000	-
BSE	590078	MAITHANALL	09-08-19	Dividend - Rs 6.0000	-
BSE	500790	NESTLEIND	09-08-19	Interim Dividend - Rs 23.0000	13-08-19
BSE	500790	NESTLEIND	09-08-19	Special Dividend - Rs 180.0000	13-08-19
BSE	532419	SMARTLINK	09-08-19	Buy Back of Shares	13-08-19
BSE	517385	SYMPHONY	09-08-19	Interim Dividend - Rs 1.0000	13-08-19
BSE	504966	TINPLATE	09-08-19	Dividend - Rs 2.0000	-




PARTICIPANT WISE OPEN INTEREST

Long Position




Short Position




MARKET MOVERS (1 MONTH CHANGE)

Nifty Movers



NSE Sectoral Indices Performance





Result Calendar Q1FY20						
BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date	
509480	BERGEPAINT	05-Aug-19	539043	BKMINDST	06-Aug-19	
540047	DBL	05-Aug-19	540073	BLS	06-Aug-19	
500850	INDHOTEL	05-Aug-19	502219	BOROSIL	06-Aug-19	
532814	INDIANB	05-Aug-19	502137	DECCANCE	06-Aug-19	
517569	KEI	05-Aug-19	532511	EXCELCROP	06-Aug-19	
503806	SRF	05-Aug-19	501848	GLOBOFFS	06-Aug-19	
532779	TORNTPOWER	05-Aug-19	508486	HAWKINCOOK	06-Aug-19	
523261	VENKYS	05-Aug-19	500187	HSIL	06-Aug-19	
532762	ACE*	05-Aug-19	500207	INDORAMA	06-Aug-19	
533227	AHLEAST	05-Aug-19	532894	INDOWIND	06-Aug-19	
539301	ARVSMART	05-Aug-19	532771	JHS	06-Aug-19	
517421	BUTTERFLY	05-Aug-19	540775	KHADIM	06-Aug-19	
540403	CLEDUCATE	05-Aug-19	540680	KIOCL	06-Aug-19	
508814	COSMOFILMS	05-Aug-19	532673	KMSUGAR	06-Aug-19	
532610	DWARKESH	05-Aug-19	532924	KOLTEPATIL	06-Aug-19	
532700	ENIL	05-Aug-19	531241	LINCPENQ	06-Aug-19	
533263	GREENPOWER	05-Aug-19	533012	LPDC	06-Aug-19	
532543	GULFPETRO	05-Aug-19	539542	LUXIND	06-Aug-19	
532859	HGS	05-Aug-19	500268	MANALIPETC	06-Aug-19	
500186	HINDOILEXP	05-Aug-19	522249	MAYURUNIQ	06-Aug-19	
532508	JSL	05-Aug-19	500298	NATPEROX	06-Aug-19	
526668	KAMATHOTEL	05-Aug-19	532670	RENUKA	06-Aug-19	
502157	MANGLMCEM	05-Aug-19	503169	RUBYMILLS	06-Aug-19	
539289	MJCO	05-Aug-19	540203	SFL	06-Aug-19	
538836	MONTECARLO	05-Aug-19	538685	SHEMAROO	06-Aug-19	
537291	NATHBIOGEN	05-Aug-19	532945	SHRIRAMEPC	06-Aug-19	
505355	NESCO	05-Aug-19	590071	SUNDARMFIN	06-Aug-19	
532366	PNBGILTS	05-Aug-19	532782	SUTLEJTEX	06-Aug-19	
524324	SEYAIND	05-Aug-19	530023	THEINVEST	06-Aug-19	
532877	SIMPLEX	05-Aug-19	507410	WALCHANNAG	06-Aug-19	
532398	UMESLTD	05-Aug-19	504067	ZENSARTECH	06-Aug-19	
520113	VESUVIUS	05-Aug-19	512587	ZODJRDMKJ	06-Aug-19	
516072	VISHNU	05-Aug-19	532921	ADANIPORTS	07-Aug-19	
535755	ABFRL	06-Aug-19	533096	ADANIPOWER	07-Aug-19	
500101	ARVIND	06-Aug-19	524804	AUROPHARMA	07-Aug-19	
515030	ASAHIINDIA	06-Aug-19	500031	BAJAJELEC	07-Aug-19	
500042	BASF	06-Aug-19	500038	BALRAMCHIN	07-Aug-19	
532885	CENTRALBK	06-Aug-19	532400	BSOFT	07-Aug-19	
532843	FORTIS	06-Aug-19	500087	CIPLA	07-Aug-19	
500690	GSFC	06-Aug-19	500480	CUMMINSIND	07-Aug-19	
535789	IBULHSGFIN	06-Aug-19	532281	HCLTECH	07-Aug-19	
532947	IRB	06-Aug-19	500104	HINDPETRO	07-Aug-19	
500380	JKLAKSHMI	06-Aug-19	530005	INDIACEM	07-Aug-19	
533148	JSWENERGY	06-Aug-19	532714	KEC	07-Aug-19	
534690	LAKSHVILAS	06-Aug-19	500257	LUPIN	07-Aug-19	
500271	MFSL	06-Aug-19	500520	M&M	07-Aug-19	
532539	MINDAIND	06-Aug-19	539332	NAVKARCORP	07-Aug-19	
523385	NILKAMAL	06-Aug-19	532466	OFSS	07-Aug-19	
513683	NLCINDIA	06-Aug-19	532522	PETRONET	07-Aug-19	
500331	PIDILITIND	06-Aug-19	503100	PHOENIXLTD	07-Aug-19	
532955	RECLTD	06-Aug-19	532524	PTC	07-Aug-19	
500413	THOMASCOOK	06-Aug-19	531500	RAJESHEXPO	07-Aug-19	
500114	TITAN	06-Aug-19	500260	RAMCOCEM	07-Aug-19	
506767	ALKYLAMINE	06-Aug-19	500550	SIEMENS	07-Aug-19	
532888	ASIANTILES	06-Aug-19	532221	SONATSOFTW	07-Aug-19	
505688	BHARATGEAR	06-Aug-19	523756	SREINFRA	07-Aug-19	
526666	BIL	06-Aug-19	500403	SUNDRMFAST	07-Aug-19	



Result Calendar Q1FY20					
BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date
500470	TATASTEEL	07-Aug-19	540153	ENDURANCE	08-Aug-19
500575	VOLTAS	07-Aug-19	532178	ENGINERSIN	08-Aug-19
532144	WELCORP	07-Aug-19	500620	GESHIP*	08-Aug-19
541450	ADANIGREEN	07-Aug-19	500670	GNFC	08-Aug-19
532749	ALLCARGO	07-Aug-19	533150	GODREJPROP	08-Aug-19
540975	ASTERDM	07-Aug-19	533248	GPPL	08-Aug-19
506820	ASTRAZEN	07-Aug-19	501455	GREAVESCOT	08-Aug-19
532507	BAGFILMS	07-Aug-19	532129	HEXAWARE	08-Aug-19
540621	BHAGYAPROP	07-Aug-19	521016	ICIL	08-Aug-19
541403	DOLLAR	07-Aug-19	539807	INFIBEAM	08-Aug-19
509557	GARFIBRES	07-Aug-19	539597	JSLHISAR	08-Aug-19
532764	GEECEE	07-Aug-19	539981	MAXINDIA	08-Aug-19
532285	GEOJITFSL	07-Aug-19	539957	MGL	08-Aug-19
506480	GOCLCORP	07-Aug-19	534309	NBCC	08-Aug-19
532980	GOKUL	07-Aug-19	513023	NBVENTURES*	08-Aug-19
533282	GRAVITA	07-Aug-19	532827	PAGEIND	08-Aug-19
532744	GTNTEX	07-Aug-19	532497	RADICO	08-Aug-19
522064 533047	HONDAPOWER	07-Aug-19	524230	RCF	08-Aug-19
	IMFA	07-Aug-19	500770	TATACHEM	08-Aug-19
506222	INCERPAND	07-Aug-19	533326	TEXRAIL	08-Aug-19
523610	INGERRAND ITI	07-Aug-19	500411 532505	THERMAX UCOBANK	08-Aug-19
532341	IZMO	07-Aug-19	532538	ULTRACEMCO	08-Aug-19 08-Aug-19
511034	JINDRILL	07-Aug-19 07-Aug-19	532350	AKSHOPTFBR	08-Aug-19
532940	JKIL	07-Aug-19 07-Aug-19	500710	AKZOINDIA	08-Aug-19
590066	KCP	07-Aug-19	532259	APARINDS	08-Aug-19
533192	KCPSUGIND	07-Aug-19	532235	ARIES	08-Aug-19
533302	KICL	07-Aug-19	540649	AVADHSUGAR	08-Aug-19
500235	KSL	07-Aug-19	540710	CAPACITE	08-Aug-19
541233	LEMONTREE	07-Aug-19	533260	CAREERP	08-Aug-19
500265	MAHSEAMLES	07-Aug-19	506390	CLNINDIA	08-Aug-19
540704	MATRIMONY	07-Aug-19	532783	DAAWAT	08-Aug-19
514326	PATSPINLTD	07-Aug-19	523618	DREDGECORP	08-Aug-19
540901	PRAXIS	07-Aug-19	505242	DYNAMATECH	08-Aug-19
523539	PRECWIRE	07-Aug-19	530117	FAIRCHEM	08-Aug-19
533295	PSB	07-Aug-19	540647	GANGESSEC	08-Aug-19
532369	RAMCOIND	07-Aug-19	539725	GOKULAGRO	08-Aug-19
532370	RAMCOSYS	07-Aug-19	539787	HCG	08-Aug-19
534139	SCHNEIDER	07-Aug-19	504036	HIRECT	08-Aug-19
520151	SHREYAS	07-Aug-19	526217	HITECHCORP	08-Aug-19
516022	STARPAPER	07-Aug-19	532761	HOVS	08-Aug-19
506655	SUDARSCHEM	07-Aug-19	517380	IGARASHI	08-Aug-19
517530	SURANAT&P	07-Aug-19	541336	INDOSTAR	08-Aug-19
519091	TASTYBIT	07-Aug-19	532774	INSPIRISYS	08-Aug-19
530199	THEMISMED	07-Aug-19	532479	ISMTLTD	08-Aug-19
514142	TTL	07-Aug-19	507580	IVP	08-Aug-19
532371	TTML	07-Aug-19	502937	KESORAMIND	08-Aug-19
538706	ULTRACAB	07-Aug-19	500243	KIRLOSIND	08-Aug-19
532729	UTTAMSUGAR	07-Aug-19	523207	KOKUYOCMLN	08-Aug-19
533252	WELINV	07-Aug-19	524280	KOPRAN	08-Aug-19
500488	ABBOTINDIA	08-Aug-19	521018	MARALOVER	08-Aug-19
512599	ADANIENT	08-Aug-19	539940	MAXVIL	08-Aug-19
539254	ADANITRANS	08-Aug-19	541195	MIDHANI	08-Aug-19
540025	ADVENZYMES	08-Aug-19	532097	MUKANDENGG	08-Aug-19
539436	COFFEEDAY	08-Aug-19	500460	MUKANDLTD	08-Aug-19
532210	CUB	08-Aug-19	508989	NAVNETEDUL NOVARTIND	08-Aug-19
531162	EMAMILTD	08-Aug-19	500672	NOVARTIND	08-Aug-19



Result Calendar Q1FY20					
BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date
500313	OILCOUNTUB	08-Aug-19	502761	BLUBLND-B	09-Aug-19
509820	PAPERPROD	08-Aug-19	533267	CANTABIL	09-Aug-19
500126	PGHL	08-Aug-19	504286	DELTAMAGNT	09-Aug-19
532387	PNC	08-Aug-19	540724	DIAMONDYD	09-Aug-19
539678	QUICKHEAL	08-Aug-19	540789	DNAMEDIA	09-Aug-19
505800	RANEHOLDIN	08-Aug-19	533176	DQE	09-Aug-19
520111	RATNAMANI	08-Aug-19	532820	ELAND	09-Aug-19
532915	RELIGARE	08-Aug-19	502865	FORBESCO	09-Aug-19
505368	REVATHI	08-Aug-19	532716	GILLANDERS	09-Aug-19
533552	RUPA	08-Aug-19	517300	GIPCL	09-Aug-19
530073	SANGHVIMOV	08-Aug-19	518029	GSCLCEMENT	09-Aug-19
570005	SCAPDVR	08-Aug-19	505720	HERCULES	09-Aug-19
534598	SEPOWER	08-Aug-19	514043	HIMATSEIDE	09-Aug-19
532776	SHIVAMAUTO	08-Aug-19	500449	HOCL	09-Aug-19
590030	SPIC	08-Aug-19	517174	HONAUT	09-Aug-19
532890	TAKE	08-Aug-19	500199	IGPL	09-Aug-19
501301	TATAINVEST	08-Aug-19	500201	INDIAGLYCO	09-Aug-19
541700	TCNSBRANDS	08-Aug-19	509496	ITDCEM	09-Aug-19
505400	TEXINFRA	08-Aug-19	520051	JAMNAAUTO	09-Aug-19
514470	WINSOMTX	08-Aug-19	520057	JTEKTINDIA	09-Aug-19
538268	WONDERLA	08-Aug-19	500234	KAKATCEM	09-Aug-19
500103	BHEL	09-Aug-19	506525	KANORICHEM	09-Aug-19
500547	BPCL	09-Aug-19	524518	KREBSBIO	09-Aug-19
500825	BRITANNIA	09-Aug-19	540650	MAGADHSUGAR	09-Aug-19
532321	CADILAHC	09-Aug-19	524404	MARKSANS	09-Aug-19
532548	CENTURYPLY	09-Aug-19	526642	MIRZAINT	09-Aug-19
533400	FCONSUMER	09-Aug-19	532376	MRO-TEK	09-Aug-19
532155	GAIL	09-Aug-19	502168	NCLIND	09-Aug-19
530001	GUJALKALI	09-Aug-19	532722	NITCO	09-Aug-19
500440	HINDALCO	09-Aug-19	533202	NITESHEST	09-Aug-19
539083	INOXWIND	09-Aug-19	538772	NIYOGIN	09-Aug-19
533293	KIRLOSENG	09-Aug-19	532481	NOIDATOLL	09-Aug-19
532865	MEGH	09-Aug-19	530367	NRBBEARING	09-Aug-19
500290	MRF	09-Aug-19	513121	ORICON	09-Aug-19
524816	NATCOPHARM	09-Aug-19	500317	OSWALAGRO	09-Aug-19
500294	NCC	09-Aug-19	500327	PILITA	09-Aug-19
533098	NHPC	09-Aug-19	513519	PITTIENG	09-Aug-19
540769	NIACL	09-Aug-19	532486	POKARNA	09-Aug-19
533106	OIL	09-Aug-19	506022	PRAKASH	09-Aug-19
534809	PCJEWELLER	09-Aug-19	514354	PREMIERPOL	09-Aug-19
500680	PFIZER	09-Aug-19	540544	PSPPROJECT	09-Aug-19
500113	SAIL	09-Aug-19	500346	PUNJCOMMU	09-Aug-19
523598	SCI	09-Aug-19	505509	RESPONIND	09-Aug-19
500387	SHREECEM	09-Aug-19	533294	RKDL	09-Aug-19
532784	SOBHA	09-Aug-19	532699	ROHLTD	09-Aug-19
500285	SPICEJET	09-Aug-19	533168	ROSSELLIND	09-Aug-19
532733	SUNTV	09-Aug-19	539404	SATIN	09-Aug-19
526881	63MOONS	09-Aug-19	526807	SEAMECLTD	09-Aug-19
513349	AJMERA	09-Aug-19	539450	SHK	09-Aug-19
524075	ALBERTDA	09-Aug-19	532310	SHREERAMA	09-Aug-19
540902	AMBER	09-Aug-19	521034	SOMATEX	09-Aug-19
518091	APCL	09-Aug-19	534425	SPECIALITY	09-Aug-19
533068	ARROWTEX	09-Aug-19	535601	SREEL	09-Aug-19
519105	AVTNPL	09-Aug-19	512531	STCINDIA	09-Aug-19
532382	BALAJITELE	09-Aug-19 09-Aug-19	517168	SUBROS	09-Aug-19
500039	BANCOINDIA	09-Aug-19	537259	SUYOG	09-Aug-19
539290	BINDALAGRO	09-Aug-19	526650	TFCILTD	09-Aug-19
333230	DINDALAGNO	03-Va8-13	320030	II CILID	03-408-13



Result Calendar Q1FY20					
BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date
507205	TI	09-Aug-19	532869	TARMAT	10-Aug-19
532375	TIPSINDLTD	09-Aug-19	539871	THYROCARE	10-Aug-19
507747	TTKHEALTH	09-Aug-19	526582	TPLPLAST	10-Aug-19
532515	TVTODAY	09-Aug-19	533540	TREEHOUSE	10-Aug-19
500429	UNIPHOS	09-Aug-19	532513	TVSELECT	10-Aug-19
504212	UNIVCABLES	09-Aug-19	514175	VARDMNPOLY	10-Aug-19
541578	VARROC	09-Aug-19	539118	VRLLOG	10-Aug-19
517015	VINDHYATEL	09-Aug-19	534392	VSSL	10-Aug-19
532613	VIPCLOTHNG	09-Aug-19	526586	WIMPLAST	10-Aug-19
532660	VIVIMEDLAB	09-Aug-19	532683	AIAENG	12-Aug-19
531266	VSTTILLERS	09-Aug-19	539523	ALKEM	12-Aug-19
523660	WATERBASE	09-Aug-19	500040	CENTURYTEX	12-Aug-19
502355	BALKRISIND	10-Aug-19	509488	GRAPHITE	12-Aug-19
500085	CHAMBLFERT	10-Aug-19	500106	IFCI	12-Aug-19
532488	DIVISLAB	10-Aug-19	500378	JINDALSAW	12-Aug-19
500940	FINOLEXIND	10-Aug-19	517334	MOTHERSUMI	12-Aug-19
500163	GODFRYPHLP	10-Aug-19	533398	MUTHOOTFIN	12-Aug-19
513599	HINDCOPPER	10-Aug-19	540425	SHANKARA	12-Aug-19
532555	NTPC	10-Aug-19	533206	SJVN	12-Aug-19
533107	RNAVAL	10-Aug-19	517506	TTKPRESTIG	12-Aug-19
519183	ADFFOODS	10-Aug-19	533269	WABAG	12-Aug-19
531978	AMBIKCO	10-Aug-19	500238	WHIRLPOOL	12-Aug-19
532212	ARCHIES	10-Aug-19	523204	ABAN	12-Aug-19
513729	AROGRANITE	10-Aug-19	533221	AHLWEST	12-Aug-19
514286	ASHIMASYN	10-Aug-19	524598	AKSCHEM	12-Aug-19
531795	ATULAUTO	10-Aug-19	507828	ANSALHSG	12-Aug-19
541143	BDL	10-Aug-19	532853	ASAHISONG	12-Aug-19
500060	BIRLACABLE	10-Aug-19	532674	BASML	12-Aug-19
533272	CEBBCO	10-Aug-19	533095	BENGALASM	12-Aug-19
512519	DONEAR	10-Aug-19	506197	BLISSGVS	12-Aug-19
521014	EUROTEXIND	10-Aug-19	532719	BLKASHYAP	12-Aug-19
533638	FLEXITUFF	10-Aug-19	524742	CAPPL	12-Aug-19
532734	GPIL	10-Aug-19	532173	CYBERTECH	12-Aug-19
509635	HINDCOMPOS	10-Aug-19	502820	DCM	12-Aug-19
590018	HISARMET	10-Aug-19	511611	DCMFINSERV	12-Aug-19
540774	IFGLEXPOR	10-Aug-19	590031	DENORA	12-Aug-19
532305	INDSWFTLAB	10-Aug-19	533208	EMAMIPAP	12-Aug-19
524652	INDSWFTLTD	10-Aug-19	532737	EMKAY	12-Aug-19
533033	ISGEC	10-Aug-19	533261	EROSMEDIA	12-Aug-19
523323	KOVAI	10-Aug-19	526729	GOLDIAM	12-Aug-19
526947	LAOPALA	10-Aug-19	532708	GVKPIL	12-Aug-19
532796	LUMAXTECH	10-Aug-19	500467	HARRMALAYA	12-Aug-19
515093	MADHAV	10-Aug-19	509675	HIL	12-Aug-19
520059	MUNJALAU	10-Aug-19	500500	HINDMOTORS	12-Aug-19
500304	NIITLTD	10-Aug-19	500189	HINDUJAVEN	12-Aug-19
532698	NITINSPIN	10-Aug-19	540136	HPL	12-Aug-19
532900	PAISALO	10-Aug-19	504741	INDIANHUME	12-Aug-19
533581	PGEL	10-Aug-19	524164	IOLCP	12-Aug-19
539150	PNCINFRA	10-Aug-19	533181	ISFT	12-Aug-19
526247	PREMEXPLQ	10-Aug-19	522285	JAYNECOIND	12-Aug-19
532826	RAJTV	10-Aug-19	500241	KIRLOSBROS	12-Aug-19
532527	RKFORGE	10-Aug-19	532998	LEHIL	12-Aug-19
517059	SALZER	10-Aug-19	530011	MANGCHEFER	12-Aug-19
504918	SANDUMA	10-Aug-19	503101	MARATHON	12-Aug-19
540497	SCHAND	10-Aug-19	532357	MUKTAARTS	12-Aug-19
530075	SELAN	10-Aug-19	532641	NDL	12-Aug-19
532509	SUPRAJIT	10-Aug-19	538019	OBIL	12-Aug-19
1				- •	6 -3



Economic Calendar					
Country	Monday 05th August July 19	Tuesday 06th August 19	Wednesday 07th August 19	Thursday 8th August 19	Friday 9th August 19
us	ISM Non-Manufacturing PMI (Jul),	JOLTs Job Openings (Jun), API Weekly Crude Oil Stock	Crude Oil Inventories, Cushing Crude Oil Inventories	Initial Jobless Claims	U.S. Baker Hughes Oil Rig Count
UK/EURO ZONE	Services PMI (Jul),				GDP (QoQ) (Q2), Manufacturing Production (MoM) (Jun), PPI (MoM) (Jul)
INDIA			Interest Rate Decision		

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

<u>Disclosures</u>: Narnolia Financial Advisors Ltd. (NFAL) (FormerlyMicrosec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFALis engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority. NFAL, it's associates, Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report, NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month, period, NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have; a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report, d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and it's associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking, Investment Banking or Brokerage service transactions. Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement-

Analyst's ownership of the stocks mentioned in the Report	NIL

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerze Limited (Formerly Microsec Commerze Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 || NarnoliaVelox Advisory Ltd. - SEBI Registered PMS: INP000005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:B.05.02568.

Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL)and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific ircumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should cons

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.